A Therapeutic DNA Vaccine Targeting HPV16 E7 in Combination with Anti-PD-1/PD-L1 Enhanced Tumor Regression and Cytotoxic Immune Responses
International Journal of Molecular Sciences · 23.10.2023 · 24 (20) · 15469
DOI: 10.3390/ijms242015469 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.10.2023. Verfasst von Xuechao Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, School of Basic Medical Science, Cheeloo College of Medicine, Shandong University, Jinan 250012, China. Hauptthemen laut MEDLINE: Vaccines, DNA, Uterine Cervical Neoplasms, Cancer Vaccines, Papillomavirus Infections. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Persistent infection of high-risk human papillomavirus (HPV) and the expression of E6 and E7 oncoproteins are the main causes of cervical cancer. Several prophylactic HPV vaccines are used in the clinic, but these vaccines have limited efficacy in patients already infected with HPV. Since HPV E7 is vital for tumor-specific immunity, developing a vaccine against HPV E7 is an attractive strategy for cervical cancer treatment. Here, we constructed an HPV16 E7 mutant that loses the ability to bind pRb while still eliciting a robust immune response. In order to build a therapeutic DNA vaccine, the E7 mutant was packaged in an adenovirus vector (Ad-E7) for efficient expression and enhanced immunogenicity of the vaccine. Our results showed that the Ad-E7 vaccine effectively inhibited tumor growth and increased the proportion of interferon-gamma (IFN-γ)-secreting CD8+ T cells in the spleen, and tumor-infiltrating lymphocytes in a mouse cervical cancer model was achieved by injecting with HPV16-E6/E7-expressing TC-1 cells subcutaneously. Combining the Ad-E7 vaccine with the PD-1/PD-L1 antibody blockade significantly improved the control of TC-1 tumors. Combination therapy elicited stronger cytotoxic T lymphocyte (CTL) responses, and IFN-γ secretion downregulated the proportion of Tregs and MDSCs significantly. The expressions of cancer-promoting factors, such as TNF-α, were also significantly down-regulated in the case of combination therapy. In addition, combination therapy inhibited the number of capillaries in tumor tissues and increased the thickness of the tumor capsule. Thus, Ad-E7 vaccination, in combination with an immune checkpoint blockade, may benefit patients with HPV16-associated cervical cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, School of Basic Medical Science, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
ORCID-Profile: Weifang Zhang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Han, X., Gao, Z., Cheng, Y., Wu, S., Chen, J., & Zhang, W. (2023). A Therapeutic DNA Vaccine Targeting HPV16 E7 in Combination with Anti-PD-1/PD-L1 Enhanced Tumor Regression and Cytotoxic Immune Responses. International Journal of Molecular Sciences, 24(20), 15469. https://doi.org/10.3390/ijms242015469
Vancouver
Han X, Gao Z, Cheng Y, Wu S, Chen J, Zhang W. A Therapeutic DNA Vaccine Targeting HPV16 E7 in Combination with Anti-PD-1/PD-L1 Enhanced Tumor Regression and Cytotoxic Immune Responses. International Journal of Molecular Sciences. 2023;24(20):15469. doi:10.3390/ijms242015469
BibTeX
@article{Han2023,
author = {Han, Xuechao and Gao, Zhixiao and Cheng, Yeping and Wu, Shuoshuo and Chen, Jianxing and Zhang, Weifang},
title = {A Therapeutic DNA Vaccine Targeting HPV16 E7 in Combination with Anti-PD-1/PD-L1 Enhanced Tumor Regression and Cytotoxic Immune Responses},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {20},
pages = {15469},
doi = {10.3390/ijms242015469}
}
EUVIMED